Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Subgroup analyses in randomized clinical trials : value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. / Drexel, Heinz; Pocock, Stuart J.; Lewis, Basil S.; Saely, Christoph H.; Kaski, Juan Carlos; Rosano, Giuseppe M.C.; Tautermann, Gerda; Huber, Kurt; Dopheide, Joern F.; Mader, Arthur; Niessner, Alexander; Savarese, Gianluigi; Schmidt, Thomas A.; Semb, Anne Grete; Tamargo, Juan; Wassmann, Sven; Clodi, Martin; Kjeldsen, Keld Per; Agewall, Stefan.

I: European Heart Journal - Cardiovascular Pharmacotherapy, Bind 8, Nr. 3, 2022, s. 302-310.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Drexel, H, Pocock, SJ, Lewis, BS, Saely, CH, Kaski, JC, Rosano, GMC, Tautermann, G, Huber, K, Dopheide, JF, Mader, A, Niessner, A, Savarese, G, Schmidt, TA, Semb, AG, Tamargo, J, Wassmann, S, Clodi, M, Kjeldsen, KP & Agewall, S 2022, 'Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy', European Heart Journal - Cardiovascular Pharmacotherapy, bind 8, nr. 3, s. 302-310. https://doi.org/10.1093/ehjcvp/pvab048

APA

Drexel, H., Pocock, S. J., Lewis, B. S., Saely, C. H., Kaski, J. C., Rosano, G. M. C., Tautermann, G., Huber, K., Dopheide, J. F., Mader, A., Niessner, A., Savarese, G., Schmidt, T. A., Semb, A. G., Tamargo, J., Wassmann, S., Clodi, M., Kjeldsen, K. P., & Agewall, S. (2022). Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 8(3), 302-310. https://doi.org/10.1093/ehjcvp/pvab048

Vancouver

Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC o.a. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy. 2022;8(3):302-310. https://doi.org/10.1093/ehjcvp/pvab048

Author

Drexel, Heinz ; Pocock, Stuart J. ; Lewis, Basil S. ; Saely, Christoph H. ; Kaski, Juan Carlos ; Rosano, Giuseppe M.C. ; Tautermann, Gerda ; Huber, Kurt ; Dopheide, Joern F. ; Mader, Arthur ; Niessner, Alexander ; Savarese, Gianluigi ; Schmidt, Thomas A. ; Semb, Anne Grete ; Tamargo, Juan ; Wassmann, Sven ; Clodi, Martin ; Kjeldsen, Keld Per ; Agewall, Stefan. / Subgroup analyses in randomized clinical trials : value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. I: European Heart Journal - Cardiovascular Pharmacotherapy. 2022 ; Bind 8, Nr. 3. s. 302-310.

Bibtex

@article{200cd7cd4a464205b3726b5c0215eab0,
title = "Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy",
abstract = "Two review articles previously published from our working group were dedicated to the selection of endpoints as well as to reasons for premature stopping of randomized clinical trials (RCTs).1,2 We there first discussed the importance of mortality and morbidity endpoints vs. softer endpoints like revascularization rates and the issue of endpoint adjudication. Second, we have shed light on the statistical methods and requirements to stop RCTs prematurely due to safety, futility, or overwhelming efficacy (vs. the control arm).The main objective of this article is now to provide the clinical cardiologist with information how to judge and interpret published subgroup analyses. The next section will summarize the situation regarding subgroup analysis and put the current article in context.",
keywords = "Cardiovascular pharmacotherapy, Randomized clinical trials, Subgroup analyses",
author = "Heinz Drexel and Pocock, {Stuart J.} and Lewis, {Basil S.} and Saely, {Christoph H.} and Kaski, {Juan Carlos} and Rosano, {Giuseppe M.C.} and Gerda Tautermann and Kurt Huber and Dopheide, {Joern F.} and Arthur Mader and Alexander Niessner and Gianluigi Savarese and Schmidt, {Thomas A.} and Semb, {Anne Grete} and Juan Tamargo and Sven Wassmann and Martin Clodi and Kjeldsen, {Keld Per} and Stefan Agewall",
year = "2022",
doi = "10.1093/ehjcvp/pvab048",
language = "English",
volume = "8",
pages = "302--310",
journal = "European Heart Journal - Cardiovascular Pharmacotherapy",
issn = "2055-6837",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Subgroup analyses in randomized clinical trials

T2 - value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy

AU - Drexel, Heinz

AU - Pocock, Stuart J.

AU - Lewis, Basil S.

AU - Saely, Christoph H.

AU - Kaski, Juan Carlos

AU - Rosano, Giuseppe M.C.

AU - Tautermann, Gerda

AU - Huber, Kurt

AU - Dopheide, Joern F.

AU - Mader, Arthur

AU - Niessner, Alexander

AU - Savarese, Gianluigi

AU - Schmidt, Thomas A.

AU - Semb, Anne Grete

AU - Tamargo, Juan

AU - Wassmann, Sven

AU - Clodi, Martin

AU - Kjeldsen, Keld Per

AU - Agewall, Stefan

PY - 2022

Y1 - 2022

N2 - Two review articles previously published from our working group were dedicated to the selection of endpoints as well as to reasons for premature stopping of randomized clinical trials (RCTs).1,2 We there first discussed the importance of mortality and morbidity endpoints vs. softer endpoints like revascularization rates and the issue of endpoint adjudication. Second, we have shed light on the statistical methods and requirements to stop RCTs prematurely due to safety, futility, or overwhelming efficacy (vs. the control arm).The main objective of this article is now to provide the clinical cardiologist with information how to judge and interpret published subgroup analyses. The next section will summarize the situation regarding subgroup analysis and put the current article in context.

AB - Two review articles previously published from our working group were dedicated to the selection of endpoints as well as to reasons for premature stopping of randomized clinical trials (RCTs).1,2 We there first discussed the importance of mortality and morbidity endpoints vs. softer endpoints like revascularization rates and the issue of endpoint adjudication. Second, we have shed light on the statistical methods and requirements to stop RCTs prematurely due to safety, futility, or overwhelming efficacy (vs. the control arm).The main objective of this article is now to provide the clinical cardiologist with information how to judge and interpret published subgroup analyses. The next section will summarize the situation regarding subgroup analysis and put the current article in context.

KW - Cardiovascular pharmacotherapy

KW - Randomized clinical trials

KW - Subgroup analyses

U2 - 10.1093/ehjcvp/pvab048

DO - 10.1093/ehjcvp/pvab048

M3 - Review

C2 - 34180504

AN - SCOPUS:85129998085

VL - 8

SP - 302

EP - 310

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

SN - 2055-6837

IS - 3

ER -

ID: 313707849